List of Excipients in Branded Drug BETIMOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vistakon Pharmaceuticals LLC	BETIMOL	timolol	68669-522	BENZALKONIUM CHLORIDE
Vistakon Pharmaceuticals LLC	BETIMOL	timolol	68669-522	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
Vistakon Pharmaceuticals LLC	BETIMOL	timolol	68669-522	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
Vistakon Pharmaceuticals LLC	BETIMOL	timolol	68669-522	WATER
Akorn	BETIMOL	timolol	76478-001	BENZALKONIUM CHLORIDE
Akorn	BETIMOL	timolol	76478-001	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
Akorn	BETIMOL	timolol	76478-001	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

Betimol Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 31, 2026

Betimol is a timolol maleate ophthalmic solution used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Its commercial position is mature: the product relies on a well-established active ingredient, a conventional aqueous formulation, and sterile ophthalmic manufacturing. The main opportunities are preservative-free delivery, improved multidose packaging, ocular-surface tolerability, differentiated dosing, and low-cost generic supply.

Betimol’s core formulation contains timolol maleate equivalent to timolol, benzalkonium chloride as preservative, phosphate buffers, sodium hydroxide for pH adjustment, and water for injection. The formulation is technically accessible to established ophthalmic manufacturers, which limits the strength of formulation-based barriers to entry. [1]

What excipients are used in Betimol ophthalmic solution?

Betimol is supplied in 0.25% and 0.5% strengths. The listed inactive ingredients are benzalkonium chloride, sodium phosphate monobasic, sodium phosphate dibasic, sodium hydroxide, and water for injection. The product pH is approximately 6.5 to 7.5. [1]

Formulation element	Betimol role	Commercial and technical assessment
Timolol maleate	Active beta-adrenergic blocker	Established API with broad generic availability
Benzalkonium chloride, 0.01%	Preservative	Supports multidose packaging but creates ocular-surface tolerability concerns
Sodium phosphate monobasic	Buffer component	Controls pH and supports product stability
Sodium phosphate dibasic	Buffer component	Works with monobasic phosphate to maintain pH
Sodium hydroxide	pH adjustment	Manufacturing-process excipient rather than a primary differentiator
Water for injection	Vehicle	Standard sterile ophthalmic vehicle

The formulation is conventional and does not depend on a complex delivery platform, suspension technology, lipid system, polymeric depot, or device-linked release mechanism.

Why does Betimol use benzalkonium chloride?

Benzalkonium chloride, commonly abbreviated BAK, provides antimicrobial preservation for a multidose ophthalmic bottle. It is inexpensive, widely used, and compatible with established sterile filling processes.

The tradeoff is chronic ocular-surface exposure. BAK has been associated with epithelial toxicity, tear-film disruption, inflammation, and worsening discomfort in patients receiving long-term topical glaucoma therapy. These concerns create the clearest formulation opportunity around Betimol. [2]

What excipient strategy best supports a Betimol generic?

The lowest-risk strategy is to reproduce the established aqueous, buffered, BAK-preserved formulation for an ANDA. The higher-value strategy is to develop a preservative-free or reduced-preservative presentation supported by a suitable container-closure system.

Strategy	Primary benefit	Main constraint	Commercial positioning
BAK-preserved multidose solution	Lowest formulation and packaging cost	Ocular-surface tolerability	Commodity generic
Preservative-free unit-dose solution	Avoids chronic BAK exposure	Higher packaging, filling, and logistics cost	Premium chronic-use product
Preservative-free multidose bottle	Better convenience than unit doses	Requires validated microbial protection from the package	Differentiated specialty generic
Alternative preservative system	May improve tolerability	Compatibility and regulatory comparability work	Niche line extension
Low-BAK formulation	Reduces preservative burden	May not eliminate tolerability concerns	Incremental differentiation
Viscosity-enhanced solution	Longer ocular residence time	Blurring, drop size, comfort, and dosing variability	Potential 505(b)(2) product
Timolol combination product	Fewer administration steps	Combination development and competitive pressure	Glaucoma portfolio expansion

For a direct generic, changes to concentration, buffer system, preservative level, or container may increase equivalence and pharmaceutical-development requirements. A formulation that departs materially from the reference product may be better suited to a 505(b)(2) strategy rather than a conventional ANDA. FDA’s ANDA framework generally expects the proposed product to match the reference drug in active ingredient, dosage form, route of administration, strength, and other relevant characteristics. [3]

What are the main preservative-free opportunities for Betimol?

Preservative-free unit-dose vials

Unit-dose packaging is the most straightforward preservative-free option. It removes the need for BAK and reduces the risk of in-use contamination when each container is discarded after administration.

The disadvantages are higher packaging cost, larger package volume, more waste, and reduced convenience for patients taking drops over many years. A unit-dose product is most attractive for:

• Patients with ocular-surface disease
• Patients using multiple preserved glaucoma medications
• Postoperative or specialty ophthalmology channels
• Hospital and ambulatory-care settings
• Markets where preservative-free glaucoma products command a price premium

Preservative-free multidose containers

A preservative-free multidose bottle can provide better convenience and lower waste than unit-dose packaging. The commercial value depends on the container’s ability to prevent microbial ingress during repeated use.

Relevant technologies include mechanically protected dispensing tips, one-way valves, collapsible containers, airless systems, and filters. These systems can create meaningful device and combination-product intellectual property even when the timolol formulation itself is old.

The principal development risks are extractables and leachables, dose uniformity, priming behavior, residual volume, microbial integrity, and user handling. Packaging patents may provide stronger protection than formulation patents in this segment.

Alternative preservatives

Alternative preservatives can reduce reliance on BAK, but substitution alone does not guarantee improved tolerability. Candidate systems must be assessed for antimicrobial effectiveness, active-ingredient compatibility, ocular comfort, container interaction, and regulatory acceptability.

An alternative-preservative product may have commercial value when supported by comparative tolerability data. Without clinical or real-world evidence, it may be difficult to defend a price premium against low-cost BAK-preserved timolol.

What patents protect Betimol and timolol ophthalmic products?

Betimol is based on an old active ingredient and a conventional ophthalmic solution. The commercially relevant intellectual-property opportunity is therefore unlikely to reside in basic timolol composition-of-matter protection.

Potential protection categories include:

Patent category	Relevance to Betimol	Barrier strength
Timolol composition of matter	Historical only	Expired or commercially immaterial
Timolol maleate ophthalmic solution	Potentially historical	Generally weak for new entry
BAK-preserved formulation	Limited differentiation	Usually easy to design around
Buffer and pH system	Narrow technical protection	Low to moderate
Preservative-free formulation	Possible line-extension protection	Moderate if supported by unexpected results
Multidose container	Device-specific	Moderate to strong if claims are narrow and valid
Viscosity-enhanced formulation	Potential 505(b)(2) opportunity	Moderate
Combination glaucoma product	Method and formulation claims	Variable
Manufacturing process	May protect yield or sterility controls	Usually weak against independent manufacture
Method-of-use claims	May cover dosing or patient subgroup	Potentially narrow

The FDA Orange Book is the controlling source for patents and regulatory exclusivity listed for approved drug products. [4] For an old timolol solution, the principal entry risk generally comes from abbreviated applications and therapeutic substitution rather than from a strong active-ingredient patent estate.

When does Betimol lose exclusivity?

Betimol’s commercial exclusivity is already mature. Timolol ophthalmic products have been marketed for decades, and the conventional formulation is exposed to generic competition.

Exclusivity category	Betimol assessment
New chemical entity exclusivity	Expired
Five-year chemical exclusivity	Not commercially relevant
Three-year clinical-investigation exclusivity	Not expected to remain relevant for the legacy product
Pediatric exclusivity	No current commercial significance identified
Orphan-drug exclusivity	Not applicable to routine glaucoma treatment
Patent-based exclusivity	Any remaining rights would depend on current Orange Book listings
Biosimilar exclusivity	Not applicable

The product’s practical exclusivity position is determined by its old approval history, generic availability, patent listings, and any product-specific regulatory status in the FDA Orange Book. [4]

What is the Orange Book status of Betimol?

Betimol is a small-molecule ophthalmic drug, not a biologic. It is therefore subject to the generic-drug framework rather than the biosimilar framework.

The Orange Book can identify:

• Approved reference listed drug status
• Therapeutic equivalents
• Listed patents
• Patent-use codes
• Patent expiration dates
• Regulatory exclusivity
• Approval holders and dosage forms

For commercial diligence, the relevant review should cover Betimol 0.25% and 0.5% ophthalmic solutions separately, along with other timolol maleate ophthalmic solutions that may be therapeutically substitutable. Orange Book therapeutic-equivalence codes can influence pharmacy substitution and market-share erosion. [4]

Which companies are challenging Betimol with generic products?

Competition comes primarily from generic ophthalmic manufacturers and branded-generic suppliers. The relevant competitive set includes products marketed as timolol maleate ophthalmic solution in 0.25% and 0.5% strengths.

Generic competition can arise through:

• ANDA approvals for the same concentration
• Authorized-generic supply
• Hospital-contract products
• Retail pharmacy substitution
• Combination products containing timolol and another glaucoma active
• Preservative-free ophthalmic offerings

The market is broader than Betimol because physicians can prescribe another timolol maleate solution without preserving the Betimol brand. This reduces the value of brand-specific manufacturing or formulation assets unless they offer a clear tolerability, convenience, or supply advantage.

What FDA pathway applies to a new Betimol formulation?

ANDA pathway

An ANDA is the most efficient route for a formulation that remains pharmaceutically equivalent and bioequivalent to the reference product. For an ophthalmic solution, development typically focuses on:

• Active-ingredient identity and strength
• pH
• Osmolality
• Appearance and clarity
• Preservative content
• Impurity profile
• Sterility
• Container-closure integrity
• Drop size and delivered volume
• Stability
• Microbial limits and preservative effectiveness, when applicable

FDA’s ophthalmic product guidance emphasizes product quality, sterility, container performance, and controls relevant to topical ocular delivery. [5]

505(b)(2) pathway

A 505(b)(2) application may be more suitable for:

• A preservative-free multidose presentation
• A novel container-closure system
• A different concentration or dosing schedule
• A sustained-residence formulation
• A new combination product
• A new patient population or method of use

A 505(b)(2) product can rely partly on FDA’s prior findings for timolol while generating additional data for the changed formulation, device, or clinical use. Patent certification and exclusivity analysis would depend on the specific reference products and listed patents.

What manufacturing and intellectual-property barriers affect Betimol?

The manufacturing barriers are moderate for sterile ophthalmic manufacturers and high for companies without established aseptic infrastructure.

Key controls include:

• Sterile compounding
• Validated sterile filtration, where applicable
• Aseptic filling
• Container-closure integrity
• Particulate control
• Preservative concentration uniformity
• In-use stability
• Drop-volume consistency
• Extractables and leachables
• Microbial contamination prevention

The basic BAK-preserved solution is unlikely to create a durable manufacturing moat. More defensible assets may arise from:

1. A preservative-free multidose container.
2. A low-surface-volume bottle that improves dose efficiency.
3. A validated filling process that reduces particulate and sterility risk.
4. A stable formulation with reduced preservative exposure.
5. A package that maintains microbial integrity after repeated dosing.
6. A formulation-device combination with clinical tolerability data.

What litigation and settlement risks affect Betimol?

The main litigation exposure for a new Betimol generic would arise from patent certifications, manufacturing patents, device patents, or method-of-use patents associated with a specific reference product or line extension.

For a legacy timolol solution, commercial litigation risk is generally lower than for recently launched small-molecule products with active formulation patents. The more relevant legal issues are:

• Paragraph IV certifications against any listed patents
• Patent-term calculations
• Patent-use-code scope
• Induced-infringement risk for glaucoma indications
• Device-patent claims covering preservative-free delivery
• Settlement restrictions affecting generic launch timing
• Product-liability exposure tied to sterility or ocular injury

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework. If litigation is filed within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments. [6]

No biosimilar challenge applies because timolol is a synthetic small molecule, not a biologic.

How does Betimol compare with competing glaucoma formulations?

Product type	Preservative profile	Patient value	Development complexity	Commercial outlook
Betimol-style BAK solution	Preserved	Standard	Low	Price-driven generic market
Preservative-free timolol unit dose	No BAK	Higher for sensitive patients	Moderate	Premium niche
Preservative-free multidose timolol	No BAK	High convenience and tolerability potential	High	Strongest formulation opportunity
Timolol plus carbonic-anhydrase inhibitor	Varies	Fewer bottles and dosing steps	Moderate to high	Competitive combination segment
Timolol gel-forming solution	Often preserved or product-specific	Potentially lower dosing frequency	Moderate	Differentiated but clinically dependent
Prostaglandin analog	Varies	Often once daily	Established	Major competitive substitute

Betimol competes clinically with prostaglandin analogs, carbonic-anhydrase inhibitors, alpha agonists, and fixed-combination products. Timolol’s disadvantages include systemic beta-blocker effects, contraindications in certain pulmonary and cardiovascular patients, and the need for careful patient selection. Its advantages include low API cost, long clinical experience, and broad physician familiarity.

What commercial opportunities exist for Betimol?

Low-cost generic supply

The largest volume opportunity is a reliable, low-cost generic solution. Success depends on manufacturing efficiency, shortage avoidance, pharmacy coverage, and contract access rather than patent exclusivity.

Preservative-free premium product

A preservative-free product can target patients with dry eye, blepharitis, allergic conjunctivitis, chronic topical exposure, or intolerance to BAK. The value proposition is stronger when supported by ocular-surface outcomes rather than by excipient substitution alone.

Combination products

Timolol combinations can reduce the number of daily administrations and bottles. Potential partners include companies with established glaucoma portfolios, ophthalmology sales forces, or proprietary delivery platforms.

Emerging-market access

Timolol has a favorable cost profile for lower-income markets. Commercial opportunities include:

• Local sterile manufacturing
• Regional licensing
• Government procurement
• Hospital tenders
• Multi-strength portfolios
• Supply agreements with ophthalmology distributors

The main barriers are regulatory registration, sterile capacity, local pharmacopoeial compliance, and dependable supply-chain performance.

Licensing opportunities

The most valuable licensing asset is unlikely to be the timolol API. It is more likely to be:

• A preservative-free multidose container
• A validated ophthalmic delivery platform
• A combination product
• A stable formulation suitable for hot and humid climates
• A manufacturing process that improves yield or reduces sterility failures

What revenue exposure does Betimol create?

Betimol-specific revenue is generally difficult to isolate because timolol ophthalmic sales may be reported within broader ophthalmology or branded-generic portfolios. The commercial exposure should be modeled through market share, net price, dosage strength, payer channel, and substitution rates rather than through the Betimol brand alone.

A basic revenue model is:

Revenue = treated patients x bottles per year x net realized price x market share

For a mature product, the main variables are:

• Generic price erosion
• Formulary placement
• Pharmacy substitution
• Preservative-free premium
• Unit-dose versus multidose packaging
• Contract manufacturing margin
• Supply reliability
• Geographic registration coverage

Key Takeaways

• Betimol is a mature timolol maleate ophthalmic solution with a conventional excipient system.
• Its listed excipients are benzalkonium chloride, phosphate buffers, sodium hydroxide, and water for injection.
• BAK preservation supports low-cost multidose packaging but creates the clearest opportunity for product differentiation.
• A preservative-free multidose container is the strongest technical and commercial opportunity.
• A conventional generic would face limited formulation barriers and substantial price competition.
• New formulations may require a 505(b)(2) strategy if they depart materially from the reference product.
• Betimol has no biosimilar risk because timolol is a synthetic small molecule.
• The most defensible intellectual property may cover packaging, delivery systems, combination products, or specific formulation-performance characteristics.
• Generic launch risk is driven more by substitution and market access than by active-ingredient patent protection.
• Licensing value is concentrated in preservative-free delivery, ophthalmic devices, combination products, and sterile-manufacturing capabilities.

FAQs

Is benzalkonium chloride required in Betimol?

No. BAK is used to preserve the conventional multidose Betimol solution, but a preservative-free product can use unit-dose packaging or a validated preservative-free multidose container.

Can a company make a preservative-free generic timolol product?

Yes, but the regulatory pathway depends on the formulation and container differences. A direct ANDA may be possible in some circumstances; a materially different formulation or delivery system may require a 505(b)(2) application.

Does timolol have biosimilar competition?

No. Timolol is a synthetic small-molecule drug. Competition proceeds through generic-drug pathways, including ANDAs, rather than biosimilar applications.

What is the most valuable patent strategy for a new Betimol product?

The strongest opportunities are likely to involve preservative-free multidose packaging, container-closure technology, combination products, or formulation claims supported by clinically relevant tolerability or dosing advantages.

Is Betimol still commercially differentiated from generic timolol?

Only to a limited extent. The established brand may retain recognition, but generic timolol solutions are the primary competitive constraint. Differentiation would require preservative-free delivery, improved packaging, supply reliability, or evidence of better ocular-surface tolerability.

References

1. National Library of Medicine. (n.d.). Betimol- timolol maleate solution. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. European Glaucoma Society. (2020). Terminology and guidelines for glaucoma, 5th edition. British Journal of Ophthalmology, 105(1), 1-169. https://bjo.bmj.com/content/105/Suppl_1/1

3. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submissions

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

6. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/hatch-waxman-amendments-and-abbreviated-new-drug-applications